Paper28292939
A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.
Chien MH and 8 others. Mol Cancer Ther, 2017. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio. Papers, record 28292939. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28292939
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.
- PubMed
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Antibody-Dependent Cell Cytotoxicity | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Fas Ligand Protein | Major topic |
| Glycoproteins | Major topic |
| Mouth Neoplasms | Major topic |
| Recombinant Fusion Proteins | Major topic |
| fas Receptor | Major topic |
| Animals | |
| Antigens, Neoplasm | |
| Cell Line, Tumor | |
| Cell Survival | |
| Cell Transformation, Neoplastic | |
| Disease Models, Animal | |
| Humans | |
| Mice | |
| Prognosis | |
| Protein Binding | |
| Single-Chain Antibodies | |
| Tumor Burden | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 AI116725 | NIAID NIH HHS | United States | R01AI116725 | PubMed and NIH | NIH RePORTER |
| R01 DK105833 | NIDDK NIH HHS | United States | R01DK105833 | PubMed and NIH | NIH RePORTER |
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17406307 | Subcellular imaging in the live mouse. | Nat Protoc | 2006 | https://conductscience.org/library/papers/17406307 | PubMed |
| 2 | 17482535 | The CD95 receptor: apoptosis revisited. | Cell | 2007 | https://conductscience.org/library/papers/17482535 | PubMed |
| 3 | 19411038 | Major advances in the knowledge and understanding of the epidemiology, aetiopathogenesis, diagnosis, management and prognosis of oral cancer. | Oral Oncol | 2009 | https://conductscience.org/library/papers/19411038 | PubMed |
| 4 | 12654254 | NF-kappaB in cancer: a marked target. | Semin Cancer Biol | 2003 | https://conductscience.org/library/papers/12654254 | PubMed |
| 5 | 17406431 | Whole-body imaging with fluorescent proteins. | Nat Protoc | 2006 | https://conductscience.org/library/papers/17406431 | PubMed |
| 6 | 22508480 | Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. | Oncogene | 2013 | https://conductscience.org/library/papers/22508480 | PubMed |
| 7 | 10537320 | Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. | Cancer Res | 1999 | https://conductscience.org/library/papers/10537320 | PubMed |
| 8 | 12657360 | Apoptotic signaling cascades. | Prog Neuropsychopharmacol Biol Psychiatry | 2003 | https://conductscience.org/library/papers/12657360 | PubMed |
| 9 | 19266094 | The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. | PLoS One | 2009 | https://conductscience.org/library/papers/19266094 | PubMed |
| 10 | 11375993 | Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). | J Biol Chem | 2001 | https://conductscience.org/library/papers/11375993 | PubMed |
| 11 | 11212252 | Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. | Cancer Res | 2001 | https://conductscience.org/library/papers/11212252 | PubMed |
| 12 | 15486063 | Induction of tolerance using Fas ligand: a double-edged immunomodulator. | Blood | 2005 | https://conductscience.org/library/papers/15486063 | PubMed |
| 13 | 22902507 | Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. | Cancer Lett | 2013 | https://conductscience.org/library/papers/22902507 | PubMed |
| 14 | 22434316 | Tumor associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma. | Pathol Oncol Res | 2012 | https://conductscience.org/library/papers/22434316 | PubMed |
| 15 | 10702789 | Tumor-associated glycoprotein 72 (TAG-72) expression in salivary gland neoplasia: an immunohistochemical study using the monoclonal antibody (MAb) CC49. | Oral Dis | 2000 | https://conductscience.org/library/papers/10702789 | PubMed |
| 16 | 23497165 | A recombinant scFv-FasLext as a targeting cytotoxic agent against human Jurkat-Ras cancer. | J Biomed Sci | 2013 | https://conductscience.org/library/papers/23497165 | PubMed |
| 17 | 26422835 | Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. | Nat Rev Cancer | 2015 | https://conductscience.org/library/papers/26422835 | PubMed |
| 18 | 19794494 | Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. | Nature | 2009 | https://conductscience.org/library/papers/19794494 | PubMed |
| 19 | 9547332 | Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. | J Exp Med | 1998 | https://conductscience.org/library/papers/9547332 | PubMed |
| 20 | 25656654 | The role of CD95 and CD95 ligand in cancer. | Cell Death Differ | 2015 | https://conductscience.org/library/papers/25656654 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40593750 | Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy. | Nat Commun | 2025 | https://conductscience.org/library/papers/40593750 | PubMed |
| 40445465 | The CRISPR-Cas revolution in head and neck cancer: a new era of targeted therapy. | Funct Integr Genomics | 2025 | https://conductscience.org/library/papers/40445465 | PubMed |
| 38534392 | Eye Drop with Fas-Blocking Peptide Attenuates Age-Related Macular Degeneration. | Cells | 2024 | https://conductscience.org/library/papers/38534392 | PubMed |
| 38068849 | Protective Effect of Alpha-Linolenic Acid on Human Oral Squamous Cell Carcinoma Metastasis and Apoptotic Cell Death. | Nutrients | 2023 | https://conductscience.org/library/papers/38068849 | PubMed |
| 35682983 | Serum Proteomics in Patients with Head and Neck Cancer: Peripheral Blood Immune Response to Treatment. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35682983 | PubMed |
| 35249111 | FAS receptor regulates NOTCH activity through ERK-JAG1 axis activation and controls oral cancer stemness ability and pulmonary metastasis. | Cell Death Discov | 2022 | https://conductscience.org/library/papers/35249111 | PubMed |
| 33671651 | sFasL-The Key to a Riddle: Immune Responses in Aging Lung and Disease. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33671651 | PubMed |
| 31555392 | Evaluation of IC50 levels immediately after treatment with anticancer reagents using a real-time cell monitoring device. | Exp Ther Med | 2019 | https://conductscience.org/library/papers/31555392 | PubMed |
| 31455874 | Inferring novel genes related to oral cancer with a network embedding method and one-class learning algorithms. | Gene Ther | 2019 | https://conductscience.org/library/papers/31455874 | PubMed |
| 30308958 | Molecular Markers of Anticancer Drug Resistance in Head and Neck Squamous Cell Carcinoma: A Literature Review. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/30308958 | PubMed |
| 28673349 | Site-specific chemical conjugation of human Fas ligand extracellular domain using trans-cyclooctene - methyltetrazine reactions. | BMC Biotechnol | 2017 | https://conductscience.org/library/papers/28673349 | PubMed |
Genes17
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28292939
GET https://conductscience.org/api/papers/v1/28292939/references?page=2